Orbus Therapeutics

Executive Summary

Orbus Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing treatments for rare, life-threatening diseases with high unmet need. Its lead program, eflornithine, targets anaplastic astrocytoma (AA3, Grade 3 glioma), an aggressive brain cancer lacking effective therapies. Leveraging a well-characterized molecule with an established safety profile, Orbus aims to provide a new standard of care for this underserved population. The company recently completed enrollment in a pivotal Phase 3 trial (STELLAR) evaluating eflornithine as maintenance therapy in high-risk AA3 patients, with top-line data expected in the near term. If positive, eflornithine could address a significant gap in glioma treatment, offering potential survival benefits with manageable toxicity. The global addressable market for AA3 is estimated at several thousand patients annually, with premium pricing supported by orphan drug designation in both the US and EU. Orbus's focused strategy and experienced management team position it for potential regulatory submission and commercialization. However, as a private company, capital constraints and reliance on trial results heighten risk. Near-term catalysts include Phase 3 data readout, regulatory updates, and potential partnership interest, which could drive value inflection.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 STELLAR Trial Top-Line Data60% success
• Q2 2027NDA Submission to FDA50% success
• H2 2026Strategic Partnership or Licensing Deal40% success